Search

Your search keyword '"Polman,CH"' showing total 675 results

Search Constraints

Start Over You searched for: Author "Polman,CH" Remove constraint Author: "Polman,CH"
675 results on '"Polman,CH"'

Search Results

1. A knowledge-driven interaction analysis reveals potential neurodegenerative mechanism of multiple sclerosis susceptibility.

2. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci

3. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients

4. One year follow up study of primary and transitional progressive multiple sclerosis

5. Making a diagnosis in patients with an isolated spinal cord syndrome

6. Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study

7. Interferon beta-1b-neutralizing antibodies 5 years after clinically istolated syndrome

8. consideration on discontinuing natalizumab for the treatment of multiple sclerosis

9. lomg-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5 year active treatment extension of the phase 2 BENEFIT trial

10. A three-year, multi-parametric MRI study in patients at presentation with CIS

11. MRI in the diagnosis of MS: expanding the concept of 'no better explanation'

12. Assessment of the predictive role of MRI measures of brain damage in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis : a multiparametric, large-scale, multicentre study

13. Oral fingolimod (FTY720) for relapsing multiple sclerosis

15. MRI criteria for diagnosing MS in patients with a clinically isolated sybdrome

16. The effect of IFN beta-1b on the evolution of enhancing lesions in secondary progressive

17. A 1-year serial clinical and MRI study of primary progressive multiple sclerosis

18. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials

19. Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI

20. MR outcome parameters in multiple sclerosis: comparison of surface-based thresholding segmentation and magnetization transfer ratio histographic analysis in relation to disability (a preliminary note)

21. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

22. Primary progressive multiple sclerosis

23. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL

24. Effect of early versus delayed interferon beta-1b treatment on desability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

25. The incidence and significance of anti-natalizumab antibodies. Results from the AFFIRM and SENTINEL

27. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

36. Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data

37. Ophthalmoplegic and lower cranial nerve variants merge into each other and into classical Guillain-Barre syndrome

38. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development

40. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration

43. Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis

Catalog

Books, media, physical & digital resources